Your 30-Second Primer on this Week’s Hottest IPO, Spark Therapeutics
Insights - Spark Therapeutics (ONCE) lists publicly today, joining companies like bluebird bio (BLUE) and Avalanche (AAVL) as yet another emerging gene therapy player.
Read NowzFree
Intercept Gains a Cool Billion in After Hours Trading
Insights - Intercept Pharmaceuticals (ICPT) added over $1 billion to its value in late trading when its lead drug received a Breakthrough Therapy Designation
Read Now
Wall Street is Behind the Curve on Foreign Exchange Impact
Insights - Across the market, multinational companies are blaming missed earnings and lower-than-expected 2015 guidance on foreign exchange effects and cheap oil.
Read Now
Regeneron’s New Cholesterol Drug is a Month Ahead of Amgen’s: Is that Worth $70 Million?
Insights - That's what Regeneron (REGN) and Sanofi (SNY) paid for a FDA Priority Review Voucher that will shorten the review time for the PCSK9 inhibitor, alirocumab.
Read Now
The Highest Biotech Fliers Last Week were the Hardest Hit this Week
“New” Tekmira Emerges as HBV Frontrunner
Research - This is the first clinical step for “new Tekmira”. Announced last week, Tekmira is merging with OnCore Biopharma to focus on therapeutics for Hepatitis B.
Read Now
Medivation Reports Success in Latest Cancer Trial
Insights - The trial was successful, with enzalutamide improving progression-free survival (PFS) meaningfully compared to bicalutamide.
Read Now